company background image
BOUL

Boule Diagnostics OM:BOUL Stock Report

Last Price

kr36.70

Market Cap

kr712.6m

7D

1.9%

1Y

-35.7%

Updated

28 Jun, 2022

Data

Company Financials +
BOUL fundamental analysis
Snowflake Score
Valuation6/6
Future Growth4/6
Past Performance2/6
Financial Health4/6
Dividends1/6

BOUL Stock Overview

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics.

Boule Diagnostics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Boule Diagnostics
Historical stock prices
Current Share Pricekr36.70
52 Week Highkr61.90
52 Week Lowkr32.10
Beta0.81
1 Month Change-0.54%
3 Month Change-22.25%
1 Year Change-35.73%
3 Year Change-29.69%
5 Year Change-51.87%
Change since IPO213.01%

Recent News & Updates

Shareholder Returns

BOULSE Medical EquipmentSE Market
7D1.9%4.5%1.1%
1Y-35.7%-34.4%-20.9%

Return vs Industry: BOUL underperformed the Swedish Medical Equipment industry which returned -34.4% over the past year.

Return vs Market: BOUL underperformed the Swedish Market which returned -20.9% over the past year.

Price Volatility

Is BOUL's price volatile compared to industry and market?
BOUL volatility
BOUL Average Weekly Movement5.6%
Medical Equipment Industry Average Movement8.5%
Market Average Movement7.4%
10% most volatile stocks in SE Market12.2%
10% least volatile stocks in SE Market4.7%

Stable Share Price: BOUL is less volatile than 75% of Swedish stocks over the past 3 months, typically moving +/- 6% a week.

Volatility Over Time: BOUL's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1956200Jesper Söderqvisthttps://www.boule.com

Boule Diagnostics AB (publ), a diagnostics company, develops, manufactures, and markets instruments and consumable products for blood diagnostics. The company provides hematology analyzers, reagents, blood controls and calibrators, and reagents rotors, as well as cleaning products under the Swelab, Medonic, and Quintus brands; and veterinary hematology and clinical chemistry analyzer and diagnostics systems under the Exigo brand. It sells its products directly in Sweden and the United States, as well as through distributors internationally.

Boule Diagnostics Fundamentals Summary

How do Boule Diagnostics's earnings and revenue compare to its market cap?
BOUL fundamental statistics
Market Capkr712.59m
Earnings (TTM)kr27.57m
Revenue (TTM)kr495.24m

25.8x

P/E Ratio

1.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BOUL income statement (TTM)
Revenuekr495.24m
Cost of Revenuekr284.41m
Gross Profitkr210.84m
Other Expenseskr183.26m
Earningskr27.57m

Last Reported Earnings

Mar 31, 2022

Next Earnings Date

Jul 18, 2022

Earnings per share (EPS)1.42
Gross Margin42.57%
Net Profit Margin5.57%
Debt/Equity Ratio49.3%

How did BOUL perform over the long term?

See historical performance and comparison

Dividends

1.5%

Current Dividend Yield

41%

Payout Ratio
We’ve recently updated our valuation analysis.

Valuation

Is BOUL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • PEG Ratio

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BOUL?

Other financial metrics that can be useful for relative valuation.

BOUL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.7x
Enterprise Value/EBITDA15.4x
PEG Ratio0.8x

Price to Earnings Ratio vs Peers

How does BOUL's PE Ratio compare to its peers?

BOUL PE Ratio vs Peers
The above table shows the PE ratio for BOUL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average872x
STIL Stille
32x44.7%kr556.5m
ADDV A ADDvise Group
3353.5x39.0%kr1.2b
CRAD B C-Rad
64.4x41.9%kr1.3b
INTEG B Integrum
37.8x-64.2%kr804.5m
BOUL Boule Diagnostics
25.8x31.0%kr712.6m

Price-To-Earnings vs Peers: BOUL is good value based on its Price-To-Earnings Ratio (25.8x) compared to the peer average (872x).


Price to Earnings Ratio vs Industry

How does BOUL's PE Ratio compare vs other companies in the European Medical Equipment Industry?

Price-To-Earnings vs Industry: BOUL is good value based on its Price-To-Earnings Ratio (25.8x) compared to the Swedish Medical Equipment industry average (35.2x)


Price to Earnings Ratio vs Fair Ratio

What is BOUL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BOUL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio25.8x
Fair PE Ratio36.6x

Price-To-Earnings vs Fair Ratio: BOUL is good value based on its Price-To-Earnings Ratio (25.8x) compared to the estimated Fair Price-To-Earnings Ratio (36.6x).


Share Price vs Fair Value

What is the Fair Price of BOUL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BOUL (SEK36.7) is trading below our estimate of fair value (SEK80.42)

Significantly Below Fair Value: BOUL is trading below fair value by more than 20%.


Price to Earnings Growth Ratio

PEG Ratio: BOUL is good value based on its PEG Ratio (0.8x)


Discover undervalued companies

Future Growth

How is Boule Diagnostics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


31.0%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: BOUL's forecast earnings growth (31% per year) is above the savings rate (0.3%).

Earnings vs Market: BOUL's earnings (31% per year) are forecast to grow faster than the Swedish market (9.7% per year).

High Growth Earnings: BOUL's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: BOUL's revenue (7% per year) is forecast to grow faster than the Swedish market (5.6% per year).

High Growth Revenue: BOUL's revenue (7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: BOUL's Return on Equity is forecast to be low in 3 years time (15.8%).


Discover growth companies

Past Performance

How has Boule Diagnostics performed over the past 5 years?

Past Performance Score

2/6

Past Performance Score 2/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-38.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BOUL has high quality earnings.

Growing Profit Margin: BOUL became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: BOUL's earnings have declined by 38.3% per year over the past 5 years.

Accelerating Growth: BOUL has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BOUL has become profitable in the last year, making it difficult to compare its past year earnings growth to the Medical Equipment industry (6.3%).


Return on Equity

High ROE: BOUL's Return on Equity (9.1%) is considered low.


Discover strong past performing companies

Financial Health

How is Boule Diagnostics's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: BOUL's short term assets (SEK258.8M) exceed its short term liabilities (SEK239.4M).

Long Term Liabilities: BOUL's short term assets (SEK258.8M) exceed its long term liabilities (SEK66.3M).


Debt to Equity History and Analysis

Debt Level: BOUL's net debt to equity ratio (37.4%) is considered satisfactory.

Reducing Debt: BOUL's debt to equity ratio has increased from 24.6% to 49.3% over the past 5 years.

Debt Coverage: BOUL's debt is not well covered by operating cash flow (19.6%).

Interest Coverage: BOUL's interest payments on its debt are well covered by EBIT (8.7x coverage).


Balance Sheet


Discover healthy companies

Dividend

What is Boule Diagnostics's current dividend yield, its reliability and sustainability?

Dividend Score

2/6

Dividend Score 2/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage


1.50%

Current Dividend Yield

Dividend Yield vs Market

Notable Dividend: BOUL's dividend (1.5%) isn’t notable compared to the bottom 25% of dividend payers in the Swedish market (1.6%).

High Dividend: BOUL's dividend (1.5%) is low compared to the top 25% of dividend payers in the Swedish market (5.26%).


Stability and Growth of Payments

Stable Dividend: BOUL has been paying a dividend for less than 10 years and during this time payments have been volatile.

Growing Dividend: BOUL's dividend payments have increased, but the company has only paid a dividend for 9 years.


Earnings Payout to Shareholders

Earnings Coverage: With its reasonably low payout ratio (40.8%), BOUL's dividend payments are well covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: BOUL is paying a dividend but the company has no free cash flows.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

2.3yrs

Average management tenure


CEO

Jesper Söderqvist (55 yo)

2.08yrs

Tenure

kr3,944,000

Compensation

Mr. Jesper Söderqvist, Ph D., served as Director at Arcoma AB since June 2020 until May 2022 and Board Member and Chief Executive Officer of Dekatria AB. He served as Chief Executive Officer of Arcoma AB u...


CEO Compensation Analysis

Compensation vs Market: Jesper's total compensation ($USD389.26K) is above average for companies of similar size in the Swedish market ($USD232.52K).

Compensation vs Earnings: Jesper's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BOUL's management team is considered experienced (2.3 years average tenure).


Board Members

Experienced Board: BOUL's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Boule Diagnostics AB (publ)'s employee growth, exchange listings and data sources


Key Information

  • Name: Boule Diagnostics AB (publ)
  • Ticker: BOUL
  • Exchange: OM
  • Founded: 1956
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Implied Market Cap: kr712.587m
  • Shares outstanding: 19.42m
  • Website: https://www.boule.com

Number of Employees


Location

  • Boule Diagnostics AB (publ)
  • Domnarvsgatan 4
  • Spånga
  • Stockholm County
  • 163 53
  • Sweden

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/06/28 00:00
End of Day Share Price2022/06/28 00:00
Earnings2022/03/31
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.